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Abstract
Up to 50% of long-term HIV infected patients, including those with systemically well-controlled infection, commonly
experience memory problems and slowness, difficulties in concentration, planning, and multitasking. Deposition of
Ab plaques is also a common pathological feature of HIV infection. However, it is not clear whether this
accumulation is due to AD-like processes, HIV-associated immunosuppression, Tat protein-induced Ab elevations,
and/or the effects of single highly active antiretroviral therapy (ART). Here we evaluated the effects of several ART
medications (Zidovudine, Lamivudine, Indinavir, and Abacavir) alone and in combination on: 1) Ab1-40, 42 generation
in murine N2a cells transfected with the human “Swedish” mutant form of APP; 2) microglial phagocytosis of FITC-
Ab1-42 peptides in cultured murine N9 microglia. We report for the first time that these antiretroviral compounds (10
μM) generally increase Ab generation (~50-200%) in SweAPP N2a cells and markedly inhibit microglial phagocytosis
of FITC-Ab1-42 peptides in murine microglia. The most significant amyloidogenic effects were observed with
combined ART (p < 0.05); suggesting certain ART medications may have additive amyloidogenic effects when
combined. As these antiretroviral compounds are capable of penetrating the blood brain barrier and reaching the
concentrations employed in the in vitro studies, these findings raise the possibility that ART may play a casual role in
the elevated Ab found in the brains of those infected with HIV. Therefore these compounds may consequently
contribute to cognitive decline observed in HIV associated neurocognitive disorders (HAND).
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Introduction
Cognitive impairment occurs in a substantial (15-50%)
proportion of HIV-infected patients [1-3]. HIV-asso-
ciated dementia (HAD) represents the most severe form
[4]. With the introduction of antiretroviral therapy
(ART), the incidence of HAD has dramatically
decreased. In the past several years, patients–both long-
term infected and treated–including those with systemi-
cally well-controlled infection, began to report milder
memory problems and slowness, difficulties in
concentration, planning, and multitasking; collectively
termed HIV-associated neurocognitive disorders
(HAND; [2]).
Although the pathological mechanism underlying
HAND is unclear, an abundance of clinical and labora-
tory investigations suggest that HIV proteins, advanced
age, and co-morbid neurodegenerative disease may
interact in an additive or even synergistic manner result-
ing in the clinical presentation of this disorder [5,6].
This is concerning as there is an estimated 60,000 HIV-
infected individuals over the age of 50 and 10,000 over
the age of 65. Furthermore, it has been predicted that
50% of prevalent acquired immunodeficiency syndrome
(AIDS) cases in the United States will fall into this older
age group by the year 2015 [7].
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imparted by ART, the prevalence of HAND is on the
rise. At present, it is not clear whether this increased
prevalence is due to the intrinsic risk of developing
dementia with age or due to other direct or indirect fac-
tors of ART. In a recent clinical study, it was found that
neurocognitive functioning significantly improved after
immune competent, HIV-infected patients discontinued
ART treatment. Moreover, this improvement continued
in the patients remaining off ART over the nearly two
year period of follow-up. Additionally, there was a lack
of substantial neurocognitive improvement with resump-
tion of ART [8].
There are several potential explanations underlying
this clinically meaningful finding. One of these is that
ART may lead to neurotoxicity [9] which is manifested
in part by dysregulated neuronal amyloid precursor pro-
tein (APP) processing and concurrent deposition of
amyloid beta (Ab) plaques in the brain.
While extracellular amyloid plaques are the primary
amyloid pathology in Alzheimer’sd i s e a s e( A D ) ,i n t r a -
neuronal amyloid accumulation or perivascular diffuse
amyloid depositions are more of a feature of HAND [3].
Strong evidence indicates this increased amyloid deposi-
tion in the brain of HIV-1-infected patients [10] as
opposed to true full blown AD-like pathology. A correla-
tion between the years of infection and amyloid deposi-
tion has also been shown [11]. Further, this amyloid
deposition is most prevalent in the hippocampus and
frontal lobe regions [12], and also observed in pyramidal
neurons and along axonal tracks in HIV infected patients.
Importantly, patients with HIV-associated encephalitis
(HIVE) had higher levels of intraneuronal Ab immunor-
eactivity compared to HIV-1 patients without HIVE. In
addition, intracellular deposition of Ab correlated with
age in the group of patients with HIVE [13]. Finally,
HAND in older populations is at least partially linked to
early signs of b-amyloidosis observed in AD, further
demonstrating the importance of Ab deposition for the
clinical outcome of HIV-1 infection. These studies raise
questions regarding possible iatrogenic mechanisms
involved in the pathogenesis of both HAND and/or AD
as a co-morbid neurodegenerative [3,13].
In the present pilot study, we investigate the potential
effects of various ART medications on neuronal Ab pro-
duction and clearance by microglial phagocytosis in
murine N2a cells transfected with the human “Swedish”
mutant form of APP (SweAPP N2a cells) and N9 micro-
glia cultures, respectively.
Methods
Antiretrovirals
The following reagents were obtained through the NIH
AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH: Zidovudine (AZT; Cat.#
3485), Abacavir (Cat.# 4680), Indinavir (Cat.# 8145), and
Lamivudine (3TC; Cat# 8146).
Neuronal Ab Production Assay
SweAPP N2a cells were seeded at 1 × 10
5 cells/well (n =
2 for each condition) in 24-well tissue-culture plates
containing 0.5 mL of complete medium (MEM medium
supplemented with 10% fetal calf serum). Cells were dif-
ferentiated prior to treatment with cAMP in 0.5 mL
Neurobasal media for 4 hours. Following differentiation,
these cells were untreated (control vehicle; PBS) or trea-
ted with ART medications both alone (10 μM) and in
combination (10 μM) for 18 hours. Ab1-40, 42 peptides
were detected directly from the conditioned media and
quantified in these samples using Ab1-40, 42 ELISA kits
in accordance with the manufacturer’s instructions.
Microglial Phagocytosis Assay
N9 microglia were seeded at 1 × 10
5 cells/well (n = 4
for each condition) in 24-well tissue-culture plates con-
taining 0.5 mL of complete medium (RPMI 1640 med-
ium supplemented with 5% fetal calf serum). In the
presence “aged” Ab1-42 peptide conjugated with FITC
( s u p p l i e db yB i o S o u r c e ,u s e da t3 0 0n Md i s s o l v e di n
dH20 and pre-incubated for 24 h at 37°C) microglia
were co-treated with retroviral drugs both alone (10
μM) and in combination (10 μM) for 0, 30, 60, 120, and
180 minutes. For fluorometric analysis, in parallel treat-
ments, the microglia were rinsed 3 times with complete
medium after collection of cell supernatants and sub-
jected to cell lysate preparation [14,15]. The total cellu-
lar protein of all groups was quantified and adjusted
using the Bio-Rad protein assay. Extracellular and cell
associated FITC-tagged Ab was quantified using an
SPECTRAmax GEMINI microplate fluorometer (Mole-
cular Devices Corp.) with an emission wavelength of
538 nm and an excitation wavelength of 485 nm. In
addition, in parallel 24-well tissue-culture plates, micro-
glial cells were incubated at 4°C with FITC-conjugated
Ab with or without the various antiretroviral treatments
as controls for non-specifically incorporated Ab. Micro-
glial cells were rinsed 3 times in Ab-free complete med-
ium, and the media was exchanged with fresh Ab-free
complete medium for 10 min both to allow for removal
of non-incorporated Ab and to promote concentration
of the Ab into phagosomes. The relative mean fluores-
cence values for each sample at 37°C and 4°C at the
indicated time points were determined by fluorometric
analysis. Relative mean values were calculated as: (mean
fluorescence value for each sample at 37°C - mean fluor-
escence value for each sample at 4°C). In this manner,
both extracellular and cell associated FITC-labeled Ab
were quantified.
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All data were normally distributed; therefore, in instances
of single mean comparisons, Levene’s test for equality of
variances followed by t-test for independent samples was
used to assess significance. In instances of multiple mean
comparisons, analysis of variance (ANOVA) was used,
followed by post-hoc comparison using Bonferonni’s
method/correction. Alpha levels were set at 0.05 for all
analyses. The statistical package for the social sciences
release 10.0.5 (SPSS Inc., Chicago, IL, USA) was used for
all data analysis.
Results
ART medications increase Ab generation in cultured
SweAPP N2a cells
ART regimens are typically comprised of two major drug
classes: protease inhibitors (PIs) and inhibitors of reverse
transcriptase. The latter is subdivided into nucleoside
reverse transcriptase inhibitors (NRTIs) and non-
nucleoside reverse transcriptase inhibitors (nNRTIs). To
examine the potential effects of a typical ART regimen on
amyloidosis, we treated SweAPP N2a cells with 10 μMc o n -
centrations of various antiretroviral compounds both alone
and in combination for 18 hours. Following ELISA of the
cultured media, we found that all compounds generally
increased (~50-200%) Ab1-40, 42 production (Figure 1).
Interestingly, significant increases were observed when anti-
retroviral compounds were used in combination (p < 0.05,
Figure 1). Although we observe considerable increases in
Ab1-40, 42 generation with all of the antiretroviral
compounds, it appears that combinations of the NRTIs
Lamivudine (3TC) and/or Abacavir, with, the PI Indinavir,
exert the most significant amyloidogenic effects. Notably,
the NRTI Zidovudine (AZT) conferred significantly less
Ab 1-40,42 production as compared to the antiretroviral
combinations mentioned above (p < 0.05; Figure 1). Taken
together, the data suggests that iatrogenic mechanisms may
in fact contribute to HAND and AD-like pathology in HIV-
infected individuals.
ART medications inhibit microglial phagocytosis of Ab 1-42
peptides
To determine whether ART could affect microglial
clearance of Ab and further promote amyloidosis, we
performed a phagocytosis assay with N9 cells in the pre-
sence of antiretroviral compounds both alone and in
combination. Following detection of FITC-tagged Ab1-42
in extracellular and cell associated fractions, we again
found that all compounds generally inhibited microglial
phagocytosis/clearance (Figure 2). All antiretroviral
compounds significantly inhibited microglial phagocyto-
sis of Ab1-42 peptides as determined by high levels of
peptide remaining in the cultured media (extracellular)
(p < 0.05, Figure 2a). In addition, a majority of the com-
pounds tested also significantly reduced levels of phago-
somal (cell associated) Ab1-42 (p<0 . 0 5 ,F i g u r e2 b ) .
Also, when comparing cell associated Ab1-42 levels of
the Indinavir/Abacavir combination to levels of these
compound alone, the differences suggest the combination
of this PI and NRTI is additive in nature (p < 0.05;
Figure 2b). Importantly, when comparing the levels of
extracellular Ab1-42 (Figure 2a) to that of cell associated
(Figure 2b) we can see that the phagocytosis/clearance
profiles are relatively congruent for each treatment condi-
tion. That is to say, when a given treatment maintains
high levels of extracellular Ab1-42, the corresponding cell
associated levels are relatively low. Not only does this
apparent relationship between extracellular and cell asso-
ciated Ab1-42 levels confirm the accuracy of the assay, but
also furthers the overall significance of the inhibition of
microglial phagocytosis by the antiretrovirals.
Discussion
Therapy with at least three ART medications has been
standard treatment for HIV infected patients for since
approximately 1995 [16]. Indeed combination ART has
dramatically reduced medical morbidity and mortality
with HIV infection, but high rates of HAND continue to
be reported [17]. Heaton and colleagues sought to deter-
mine neurocognitive impairment in large groups of HIV
+ and HIV - participants from the pre-combination
ART era (1988-1995; N = 857) and combination ART
era (2000-2007; N = 937). The rates of impairment
increased with successive disease stages in both eras:
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Figure 1 ART medications increase Ab generation in cultured
neuronal cells. Total Ab 1-40,42 peptides were analyzed in
conditioned media from SweAPP N2a cells by ELISA (n = 2 for each
condition). Data are represented as a mean ± SEM percentage of
Ab 1-40,42 peptides secreted 18 hours after antiretroviral treatment
relative to control (untreated). One-way ANOVA followed by post
hoc comparison revealed significant increases in Ab 1-40,42
production following 3TC/Indinavir, 3TC/Abacavir, and Indinavir/
Abacavir treatements (concentration of 10 μM for each individual
compound; p < 0.05).
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45% in combination ART era. In the medically asympto-
matic stage, neurocognitive impairment was significantly
more common in the ART era; indicating a possible
iatrogenic mechanism whereby ART is salutary in the
periphery, but possibly in some way deleterious in the
CNS [17]. Furthermore, the pattern of neurocognitive
impairment also differed. Patients from the pre-ART era
had more impairment in motor skills, cognitive speed,
and verbal fluency. On the other hand, ART era patients
suffered more memory (learning) and executive function
deficits. Importantly, this study showed high rates of
mild neurocognitive impairment persist at all stages of
HIV infection, despite adequate viral suppression and
immune reconstitution with combination ART [17].
In this context, we sought to identify the risk of adverse
neuropathological side effects from various ART regi-
mens in vitro. Here, we elucidate a potential mechanism
whereby antiretroviral compounds may have neurotoxic
effects, both alone and in combination. This may contri-
bute to the neurological complications that are associated
with advanced HIV infection and/or long-term ART seen
clinically. Our study shows antiretroviral compounds
m a ye f f e c t i v e l yi n c r e a s eA b generation while possessing
the capability to inhibit its clearance by preventing
microglial phagocytosis. By affecting both amyloidogenic
fronts (generation and clearance), antiretroviral treat-
ment may substantially enhance Ab aggregation and
deposition, which itself is neurotoxic.
We find the most significant amyloidogenic effects
when the antiretroviral compounds 3TC, Indinavir, and
Abacavir are used in combination (Figure 1). Also, we
observe that particular antiretrovirals, Indinavir and
Abacavir, may have detrimental additive effects on Ab
microglial clearance (Figure 2). Accordingly, it is likely
that certain 3 drug regimens may present an even
greater risk of neurological complications.
Though higher CNS-penetrating regimens have been
associated with neurocognitive improvement, recent
research demonstrates ART might also impart neurotoxic
effects; adversely affecting cognition. Indeed in a recent
clinical study discontinuation of ART in experienced sub-
jects improved neurocognition and those results were
not attributed to practice effects. Furthermore, subjects re-
initiated on ART did not experience cognitive gains.
Therefore, ART neurotoxicity might explain the unex-
pected results of this clinical study gains [8]. Past reports
have indicated the deleterious effects of ART on the brain
were at least in part caused by damage to peripheral neural
tissues (for review see [9]). NRTIs have been shown to
induce toxicity in peripheral tissues by altering mitochon-
drial function, and PIs were shown to damage proteosome
function [12,18]. Also, subjects on didanosine and stavu-
dine regimens had decreased N-acetylaspartate (NAA)
concentrations in frontal white matter, a sign of neurotoxi-
city which positively correlated with treatment duration
[19].
Recently, studies have addressed the influence of five
NRTIs (2’ 3’-dideoxyinosine, zidovudine, emtricitabine,
and tenofovir), one NNRTI (efavirenz), and two PIs
(ritonavir, atazanavir sulfate) on neuronal integrity and
function. All of the antiretroviral medications tested
except for 2’ 3’-dideoxyinosine reduced mitochondrial
membrane potential. Furthermore, several antiretroviral
medications destabilized neuronal intracellular calcium
homeostasis, showing a reduced acute response to gluta-
mate [20]. The ability of certain antiretroviral medica-
tions and combinations thereof to dysregulate neuronal
calcium homeostasis and affect the mitochondrial
Figure 2 ART medications inhibit microglial phagocytosis of
Ab1-42 peptides. N9 microglia were treated with “aged” FITC-
tagged Ab 1-42 (300 nM) in complete medium for 120 min in the
presence of 10 μM concentrations of antiretrovirals. Total FITC-Ab1-42
peptides were analyzed by fluorescence from conditioned media
(extracellular; top) and cell lysates (phagosomal/cell associated;
bottom). Data are represented as the relative mean ± SEM
fluorescence (n = 4 for each condition presented). When measuring
extracellular FITC-tagged Ab 1-42, one-way ANOVA followed by post
hoc comparison showed significantly higher levels following all
antiretroviral treatments, as compared to control (p < 0.05). When
measuring cell associated FITC-tagged Ab 1-42, one-way ANOVA
followed by post hoc comparison showed significantly lower levels
following Indinavir, Abacavir, AZT/3TC, AZT/Abacavir, 3TC/Indinavir,
and Indinavir/Abacavir, as compared to control (p < 0.05).
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plaques and increased amyloidogenic processing of APP
(for review see [21]). Furthermore, neurons treated with
antiretroviral medications exhibited dendritic beading
and pruning correlated over a range of doses, which has
been linked to cognitive dysfunction [22].
In our experiments, the median toxic doses for several
ARVs were well within the therapeutic concentration
range in plasma of HIV-infected patients, and a few
showed some signs of damage in the range of CSF con-
centrations. These initial observations highlight potential
adverse effects of high concentrations of antiretroviral
medications in the CNS and indicate that there may be
some negative tradeoffs to traditionally delivering “thera-
peutic concentrations” of these compounds to the CNS.
As previous pharmacokinetic studies have confirmed
the moderate to high oral bioavailabilities and low to
moderate plasma protein binding properties of 3TC,
Indinavir, and Abacavir, it is feasible that all of these
antiretroviral compounds can reach systemic peak con-
centrations >100 uM following normal dosing regimens.
Needless to say, only a fraction of these concentrations
needs to be distributed in the brain to mediate the amy-
loidogenic effects we observed in our in vitro studies,
which employed 10uM concentrations. Furthermore,
ART effects in vivo are likely to occur over long-term
exposures. Chronic, low dose, in vivo effects of any
reagent are often very appropriately modeled in vitro,b y
proportionately higher doses of that same reagent, over
more acute time frames [23]. For these reasons we used
10uM ART dose for these experiments.
This brings us to a potential dilemma in ART con-
cerning an important parameter, blood brain barrier
(BBB) permeability. On one hand 3TC, Abacavir, and
Indinavir have been reported to be moderately BBB
permeable and consequently may be free to promote
amyloidosis. On the other hand, these antiretroviral
compounds may also be more capable of reducing HIV
load in the brain, which may be essential to avoid gen-
eral HIV encephalopathy. Furthermore, Liu and collea-
gues [24] demonstrated that the HIV-1 Tat protein
competitively inhibits the LRP receptor, resulting in an
inhibition of Ab clearance. Therefore, by minimizing
HIV replication and associated Tat protein expression in
the brain, BBB permeable antiretroviral compounds may
also prevent amyloidosis. In light of this complex situa-
tion, switching from an ART regimen that is associated
with both amyloidosis and the potentially related lipody-
strophy to one without these adverse effects may be the
best course of clinical action to reduce the risk of neu-
rological complications. On the other hand, consistent
association of neurocognitive impairment with nadir
CD4 across pre-and post-ART eras suggests that earlier
treatment to prevent severe immunosuppression may
also help prevent HAND. Clinical trials targeting HAND
prevention should specifically examine timing of ART
initiation [2].
Future studies are also warranted to investigate the
dose-response effects of newer BBB permeable antiretro-
viral drugs including fusion inhibitors, alone and in
combination, on microglial CNS Ab levels in an in vivo
murine model. Moreover, future studies will be required
to determine the effect of antiretrovirals on APP proteo-
lysis and microglial Ab proteases including neprilysin,
insulin-degrading enzyme, and endothelin-converting
enzymes 1 and 2, as ART modulated proteolytic activity
could affect the development of HAND and amyloidosis.
This study was also limited to the effect of ART of
microglia and neurons separately without other mitigat-
ing factors. In the future this work will need to be repli-
cated in vivo in mouse models to not only account for
astrocytes, but the entire brain milieu. Nevertheless, it is
clear from the most recent update by the World Health
Organization in 2010 that the cost of rapid ART scale-
up is significant in terms of side-effects [16]. There is a
need from patients and health-care providers to phase
in less toxic ART regiments while maintaining simplified
fixed-dose combinations.
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